10/19/2021 6:48:07 AM
Lilly : Tirzepatide Results Show Superior A1C And Body Weight Reductions In Type 2 Diabetes With Increased CV Risk
10/18/2021 4:01:13 PM
Eli Lilly And Co. (LLY) Declares $ 0.85 Dividend for Q4 21, Record Date 11/15/2021
10/13/2021 6:48:42 AM
Lilly: FDA Approves Verzenio As First And Only CDK4/6 Inhibitor For People With HR+ HER2- High Risk Early Breast Cancer
10/7/2021 9:02:27 AM
Loxo Oncology At Lilly Announces Details Of Presentations On Molecular Targets And Cancer Therapeutics
9/30/2021 6:03:38 AM
Lilly Announces Detailed Results From Two Pivotal Phase 3 Trials Of BRAVE-AA1 And BRAVE-AA2 For Alopecia Areata
9/30/2021 4:55:12 AM
Lilly Says SURPASS-3 MRI Sub-study Of Tirzepatide Meets Primary And Secondary Endpoints In Adults With Type 2 Diabetes
9/30/2021 4:37:04 AM
Lilly Says SURPASS-3 CGM Sub-study Meets Primary And Secondary Endpoints In Adults With Type 2 Diabetes
9/29/2021 10:03:07 AM
Lilly, Susan G. Komen Partner To Address Disparities In Breast Cancer Outcomes Experienced By Black Women
9/28/2021 6:34:03 AM
Lilly To Lower List Price Of Insulin Lispro Injection In The U.S. By An Additional 40%, Effective Jan 1